Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran
| Autor: | Fatemeh Ahangarkani, Majid Saeedi, Zahra Akbari, Mazaher Azordeh, Ahmad Alikhani, Reza Alizadeh-Navaei, Farhang Babamahmoodi, Shirafkan Kordi, Seyed Abbas Mousavi, Akbar Hedayatizadeh-Omran, Gasem Ovaise |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty COVID-19 Vaccines Side effect Health Personnel Science Pain Diseases Iran Antibodies Viral Article law.invention Young Adult Sex Factors Medical research Randomized controlled trial law Internal medicine Epidemiology medicine Humans Young adult Adverse effect Fatigue Aged Multidisciplinary business.industry SARS-CoV-2 Immunogenicity Age Factors Health care COVID-19 Middle Aged Antibodies Neutralizing Immunity Humoral Joint pain Medicine Observational study Female medicine.symptom business |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | The Sputnik V is a COVID- 19 vaccine developed by the Gamalia institute of epidemiology and microbiology and released on August 11, 2020. We provided independent evidence on side effects and immunogenicity following the administration of the Sputnik V COVID-19 in Iran. In this observational study, the healthcare workers who were vaccinated with the Sputnik V COVID-19 vaccine within February and April 2021 were evaluated. Among a total of 13,435 vaccinated healthcare workers, we received 3236 self-declaration reports of Sputnik V associated adverse events with the mean age 39.32 ± 10.19 years old which 38.8% were men and 61.2% were women. Totally 68.8% of females versus 66.2% of males reported side effects after receiving the first dose and 31.2% of females versus 33.8% of males reported side effects after the second dose of vaccine. The most common side effect was a pain in the injection site (56.9%), fatigue (50.9%), body pain (43.9%), headache (35.7%), fever (32.9%), joint pain (30.3%), chilling (29.8%) and drowsiness (20.3%). Side effects of the vaccine were significantly more frequent in females and younger individuals. Among a total of 238 participants, more than 90% after the first and second dose of vaccine had a detectable level of SARS-CoV-2 RBD antibody and SARS-CoV-2 neutralizing antibody. Although the overall rate of adverse effects was higher than the interim results from randomized controlled trials, our findings support the manufacturer’s reports about the high humoral immunogenicity of vaccine against COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|